Kim Yong Kyun, Lim Kil-Byung, Lee Sang Chul, Park Jin-Woo, Lee Hong-Jae, Kwon Bum Sun, Lee Ho Jun
Department of Physical Medicine and Rehabilitation, Myongji Hospital, Kwandong University College of Medicine, Goyang, South Korea.
Department of Physical Medicine and Rehabilitation, Ilsan Paik Hospital, Inje University, Gimhae-si, South Korea.
Dement Geriatr Cogn Dis Extra. 2014 Oct 29;4(3):395-401. doi: 10.1159/000363622. eCollection 2014 Sep.
BACKGROUND/AIMS: In dementia patients, a deficit in activities of daily living (ADL) is one of the main problems. Our objective was to assess ADL using the Korean Modified Barthel Index (K-MBI) in patients with Alzheimer's disease (AD) plus cerebrovascular disease (CVD) treated with a rivastigmine patch for 24 weeks in an open-label, observational study.
29 patients were enrolled who met the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ ANDRA) criteria and had a score of 10-26 on the Korean version of the Mini-Mental State Examination (K-MMSE). After the rivastigmine patch had been applied for 24 weeks, changes in self-care activities were assessed using the K-MBI.
The average age of the patients was 62.8 years, and they had an average K-MMSE score of 16.2. Patients showed a mean improvement of 21.9 points, as compared with the baseline K-MBI score of 30.3 (p < 0.05). Significantly better outcomes were seen in secondary outcome variables, for example the K-MMSE and backward digit span. The most frequent adverse events were skin problems, such as itching sensation (10%).
In this multicenter, open-label, observational study, the rivastigmine patch was associated with improvements in ADL in patients with AD plus CVD.
背景/目的:在痴呆患者中,日常生活活动能力(ADL)缺陷是主要问题之一。我们的目标是在一项开放标签的观察性研究中,使用韩国改良巴氏指数(K-MBI)评估接受卡巴拉汀贴片治疗24周的阿尔茨海默病(AD)合并脑血管病(CVD)患者的ADL。
纳入29例符合美国国立神经病学、语言障碍和卒中研究所/阿尔茨海默病及相关疾病协会(NINCDS/ANDRA)标准且韩国版简易精神状态检查表(K-MMSE)得分为10-26分的患者。在应用卡巴拉汀贴片24周后,使用K-MBI评估自我护理活动的变化。
患者的平均年龄为62.8岁,平均K-MMSE得分为16.2。与基线K-MBI得分30.3相比,患者平均改善了21.9分(p<0.05)。在次要结局变量中,例如K-MMSE和倒背数字广度,观察到明显更好的结果。最常见的不良事件是皮肤问题,如瘙痒感(10%)。
在这项多中心、开放标签的观察性研究中,卡巴拉汀贴片与AD合并CVD患者的ADL改善相关。